缓解1型糖尿病新策略:以调节性T细胞为干预靶点  

A new strategy for reversing type 1 diabetes:targeting regulatory T cells

作　　者：杨雪[1] 陈煜[1] 陈国芳[1] 刘超[1] Yang Xue;Chen Yu;Chen Guofang;Liu Chao(Department of Endocrinology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Traditional Chinese Medicine,Nanjing 210028,China)

机构地区：[1]南京中医药大学附属中西医结合医院内分泌科,南京210028

出　　处：《国际内分泌代谢杂志》2023年第1期38-41,共4页International Journal of Endocrinology and Metabolism

基　　金：江苏省第十六批"六大人才高峰"项目(WSN-035)。

摘　　要：1型糖尿病主要是由T细胞介导的针对胰岛β细胞的自身免疫性疾病,主要依赖胰岛素治疗,移植疗法可有效恢复胰岛功能,但存在术后排异等问题。近来的研究发现,调节性T细胞在1型糖尿病的发生发展以及移植治疗后的免疫稳态中发挥着关键作用。以调节性T细胞为干预靶点的疗法可作为一种重要手段在1型糖尿病中减轻(消除)自身免疫,以延缓疾病进展或逆转疾病进程;应用于1型糖尿病移植治疗后,则可缓解乃至消除术后的排异反应。该策略为1型糖尿病的治疗及缓解开辟了新的思路。Type 1 diabetes is an autoimmune disease mainly mediated by T cells and targeted at islet beta cells.It mainly relies on insulin therapy.Transplantation therapy can effectively restore the function of the islet,but there are problems such as postoperative rejection.Recently,regulatory T cells have been found to play an important role in the development of type 1 diabetes and in immune homeostasis after transplantation therapy.Therapies targeting regulatory T cells may be a means to reduce/eliminate autoimmunity,delay disease progression,or reverse disease progression in type 1 diabetes;After transplantation for type 1 diabetes,it can alleviate/eliminate the rejection reaction after surgery.This strategy provides a new idea for the treatment and reversal of T1DM.

关 键 词：1型糖尿病 调节性T细胞 防治 逆转 缓解 

分 类 号：R587.1[医药卫生—内分泌]